337 related articles for article (PubMed ID: 31107887)
1. Not all moderate disease is the same - Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity.
Pan Y; Norton S; Gwinnutt JM; Kearsley-Fleet L; Symmons DPM; Lunt M; Young A; ; Hyrich KL; Verstappen SMM
PLoS One; 2019; 14(5):e0215999. PubMed ID: 31107887
[TBL] [Abstract][Full Text] [Related]
2. Health Assessment Questionnaire disability progression in early rheumatoid arthritis: systematic review and analysis of two inception cohorts.
Norton S; Fu B; Scott DL; Deighton C; Symmons DP; Wailoo AJ; Tosh J; Lunt M; Davies R; Young A; Verstappen SM
Semin Arthritis Rheum; 2014 Oct; 44(2):131-44. PubMed ID: 24925692
[TBL] [Abstract][Full Text] [Related]
3. Effect of Fatigue, Older Age, Higher Body Mass Index, and Female Sex on Disability in Early Rheumatoid Arthritis in the Treatment-to-Target Era.
Twigg S; Hensor EMA; Freeston J; Tan AL; Emery P; Tennant A; Morgan AW;
Arthritis Care Res (Hoboken); 2018 Mar; 70(3):361-368. PubMed ID: 28511291
[TBL] [Abstract][Full Text] [Related]
4. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
[TBL] [Abstract][Full Text] [Related]
5. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported Outcomes as Predictors of Change in Disease Activity and Disability in Early Rheumatoid Arthritis: Results from the Yorkshire Early Arthritis Register.
Twigg S; Hensor EMA; Emery P; Tennant A; Morgan AW;
J Rheumatol; 2017 Sep; 44(9):1331-1340. PubMed ID: 28668806
[TBL] [Abstract][Full Text] [Related]
7. Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity.
Hyrich KL; Deighton C; Watson KD; ; Symmons DP; Lunt M;
Rheumatology (Oxford); 2009 Oct; 48(10):1323-7. PubMed ID: 19706737
[TBL] [Abstract][Full Text] [Related]
8. Older age at rheumatoid arthritis onset and comorbidities correlate with less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index response to etanercept in the RADIUS 2 registry.
Martin WJ; Shim M; Paulus HE; Chaudhari S; Feng J; Elashoff D; Hahn TJ; Ranganath VK;
J Clin Rheumatol; 2014 Sep; 20(6):301-5. PubMed ID: 25160011
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
10. Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.
Alten R; Burkhardt H; Feist E; Krüger K; Rech J; Rubbert-Roth A; Voll RE; Elbez Y; Rauch C
Arthritis Res Ther; 2018 Jan; 20(1):1. PubMed ID: 29329602
[TBL] [Abstract][Full Text] [Related]
11. Early response to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RA.
Hamann PDH; Pauling JD; McHugh N; Hyrich K; Shaddick G;
Rheumatology (Oxford); 2020 Jul; 59(7):1709-1714. PubMed ID: 31714580
[TBL] [Abstract][Full Text] [Related]
12. In early arthritis patients, high HAQ at baseline and DAS28 at three months predict suboptimal outcomes at two years: a retrospective cohort study.
Fanouriakis A; Papalopoulos I; Gergianaki I; Spyrou G; Erden A; Rapsomaniki P; Terizaki M; Avgoustidis N; Repa A; Kougkas N; Bertsias G; Boumpas DT; Sidiropoulos PI
Clin Exp Rheumatol; 2018; 36(5):806-813. PubMed ID: 29533750
[TBL] [Abstract][Full Text] [Related]
13. Efficient management of rheumatoid arthritis significantly reduces long-term functional disability.
Tanaka E; Mannalithara A; Inoue E; Hara M; Tomatsu T; Kamatani N; Singh G; Yamanaka H
Ann Rheum Dis; 2008 Aug; 67(8):1153-8. PubMed ID: 17971459
[TBL] [Abstract][Full Text] [Related]
14. Twenty-Year Outcome and Association Between Early Treatment and Mortality and Disability in an Inception Cohort of Patients With Rheumatoid Arthritis: Results From the Norfolk Arthritis Register.
Gwinnutt JM; Symmons DPM; MacGregor AJ; Chipping JR; Marshall T; Lunt M; Verstappen SMM
Arthritis Rheumatol; 2017 Aug; 69(8):1566-1575. PubMed ID: 28425173
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.
Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
J Rheumatol; 2012 Feb; 39(2):240-6. PubMed ID: 22174201
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of an anti-CD20 monoclonal antibody (Reditux™) for the treatment of patients with moderate to severe rheumatoid arthritis following the failure of conventional synthetic disease-modifying anti-rheumatic drugs.
Bhati M; Bandyopadhyay S
Clin Rheumatol; 2016 Aug; 35(8):1931-1935. PubMed ID: 27334114
[TBL] [Abstract][Full Text] [Related]
17. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis.
Sung YK; Cho SK; Kim D; Choi CB; Won S; Bang SY; Cha HS; Choe JY; Chung WT; Hong SJ; Jun JB; Kim HA; Kim J; Kim SK; Kim TH; Lee HS; Lee J; Lee J; Lee SS; Lee SW; Lee YA; Nah SS; Suh CH; Yoo DH; Yoon BY; Bae SC;
Rheumatol Int; 2017 Jun; 37(6):975-982. PubMed ID: 28132102
[TBL] [Abstract][Full Text] [Related]
19. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry.
Jørgensen TS; Turesson C; Kapetanovic M; Englund M; Turkiewicz A; Christensen R; Bliddal H; Geborek P; Kristensen LE
PLoS One; 2017; 12(2):e0169946. PubMed ID: 28151971
[TBL] [Abstract][Full Text] [Related]
20. Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis.
Welsing PM; Fransen J; van Riel PL
Arthritis Rheum; 2005 Sep; 52(9):2616-24. PubMed ID: 16142762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
